NCT00091234 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19) (NCT00091234)

Trial Description
Monoclonal antibodies, including antibody-drug conjugates such as gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether gemtuzumab ozogamicin is more effective than standard supportive care in treating older patients who have acute myeloid leukemia.

This randomized phase II/III trial is studying two different gemtuzumab ozogamicin regimens to see how well they work compared to standard supportive care in treating older patients with previously untreated acute myeloid leukemia.

This trial is sponsored by European Organisation for Research and Treatment of Cancer (EORTC) [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 279
  • Start: June 2004
  • Estimated Primary Completion: December 2013

Study Schematic

Click here to Return to Drug map

Last Editorial review: September 4, 2017
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.